Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 12:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,192 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo: Normal Saline Clear all
Not listed Phase 4 Interventional

Intranasal Sufentanil Versus Intravenous Morphine for the Management of Acute Pain

NCT03224039
View directory record Official record
Conditions
Acute Pain
Interventions
Sufentanil, Normal saline, Morphine
Drug
Lead sponsor
The Brooklyn Hospital Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 10, 2026, 12:27 AM EDT
Terminated Phase 2 Interventional Results available

Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery

NCT00966654
View directory record Official record
Conditions
CABG
Interventions
Placebo, GLP-1 (7-36) amide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 10, 2026, 12:27 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

NCT04543994
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Remestemcel-L, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Phase 2 Interventional

Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

NCT00851045
View directory record Official record
Conditions
Colorectal Cancer (CRC)
Interventions
Irinotecan, 5-Fluorouracil (bolus), 5-Fluorouracil (infusional), Leucovorin calcium, CT-322, Bevacizumab, Bevacizumab Placebo (saline solution)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Tucson, Arizona • Fountain Valley, California • Riverside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Phase 2 Interventional Results available

BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis

NCT02230956
View directory record Official record
Conditions
Osteoarthritis
Interventions
onabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Not applicable Interventional Results available

Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting

NCT00585351
View directory record Official record
Conditions
Stroke
Interventions
Ranitidine, Placebo, Advanced notification, No advanced notification
Drug · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 10, 2026, 12:27 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

NCT02641639
View directory record Official record
Conditions
Platinum Resistant Ovarian Cancer
Interventions
Fosbretabulin tromethamine, Placebo
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 10, 2026, 12:27 AM EDT
Terminated Phase 3 Interventional Results available

A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

NCT02547220
View directory record Official record
Conditions
Acute Antibody-Mediated Rejection (AMR)
Interventions
Cinryze®, Placebo
Biological · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
29
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Phase 2 Interventional

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

NCT05856331
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions
SAR447537, Zemaira
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 10, 2026, 12:27 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study in Participants With Acute Migraines Headaches

NCT00804973
View directory record Official record
Conditions
Migraine Headache
Interventions
LY2590443, Placebo injection, Sumatriptan, Placebo capsule
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
19
States / cities
Beverly Hills, California • Chula Vista, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 10, 2026, 12:27 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Efficacy of Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy

NCT02712151
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Abdominal Wall Block, Surgical infiltration, Sterile saline, Ropivacaine 0.2%, Ultrasound, Ropivacaine 0.5%
Procedure · Drug · Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 10, 2026, 12:27 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

NCT03403751
View directory record Official record
Conditions
Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection
Interventions
Reltecimod 0.5 mg/kg, Placebo
Drug
Lead sponsor
Atox Bio Ltd
Industry
Eligibility
18 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Propofol and Dexmedetomidine Versus a Propofol Only Regimen for Sedation During Colonoscopy

NCT03139279
View directory record Official record
Conditions
Colonoscopy
Interventions
Dexmedetomidine, Saline placebo, Propofol
Drug · Other
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

NCT02094586
View directory record Official record
Conditions
Cholera
Interventions
PXVX0200 Lot A, PXVX0200 Lot B, PXVX0200 Lot C, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
3,146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
19
States / cities
Mobile, Alabama • Phoenix, Arizona • DeLand, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Phase 1 Interventional

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

NCT02830542
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SER-262, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 10, 2026, 12:27 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks

NCT03159000
View directory record Official record
Conditions
Migraine
Interventions
Saline, lidocaine/bupivacaine
Drug · Combination Product
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neulasta in Type 1 Diabetes

NCT00662519
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
Drug · Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)

NCT01525901
View directory record Official record
Conditions
22q13 Deletion Syndrome, Phelan-McDermid Syndrome
Interventions
Insulin-Like Growth Factor-1 (IGF-1), Normal saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
5 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Phase 2 Interventional Results available

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

NCT01713400
View directory record Official record
Conditions
Graft vs. Host Disease
Interventions
Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 10, 2026, 12:27 AM EDT
Recruiting Phase 2 Interventional

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

NCT06665100
View directory record Official record
Conditions
Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
PUL-042, Placebo
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oxytocin MEG Study

NCT02568709
View directory record Official record
Conditions
Schizophrenia, Oxytocin, Magnetoencephalography (MEG), Social Cognition
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 10, 2026, 12:27 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain

NCT04356352
View directory record Official record
Conditions
Injection Site Irritation, Pain
Interventions
Lidocaine, Esmolol, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 10, 2026, 12:27 AM EDT
Completed Phase 3 Interventional Results available

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

NCT04994535
View directory record Official record
Conditions
Platysma Prominence
Interventions
OnabotulinumtoxinA, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 10, 2026, 12:27 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT03425643
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
51
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 10, 2026, 12:27 AM EDT